GLP-1 therapies are on track to become one of the fastest-growing drug classes in history. Sales are expected to reach $100 billion by 2030. But the real opportunity is bigger than weight loss.
Obesity—once seen as an intractable condition—is now widely recognized as a treatable disease and part of a broader metabolic health crisis shaping healthcare costs, workforce productivity, and consumer demand worldwide.
“Metabolic health is a much bigger notion than just obesity. Overall, I see this as a giant economic and health opportunity. It’s going to disrupt and create opportunities across different industries,” said McKinsey Partner Lars Hartenstein in a recent episode of The McKinsey Podcast.
Explore these insights on the interventions, technologies, and opportunities shaping the next era of metabolic health.
A new way of thinking about metabolic health
The path toward a metabolic health revolution
GLP-1s are boosting demand for medical aesthetics
The future takes shape: Five dimensions of tomorrow’s wellness economy